Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression

BACKGROUND: The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients treated with ROS1 inhibitors fail to derive any clinical benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Tara L., Chen, Nan, Tyler, Logan C., Le, Anh T., Dimou, Anastasios, Doebele, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665781/
https://www.ncbi.nlm.nih.gov/pubmed/37727007
http://dx.doi.org/10.1111/1759-7714.15116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665781/
https://www.ncbi.nlm.nih.gov/pubmed/37727007
http://dx.doi.org/10.1111/1759-7714.15116

Ejemplares similares